NDA 207145 · Mdd US
Xadago
Safinamide Mesylate · Oral
NovelLast checked: Nov 19, 2026Latest source record: Aug 6, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Mar 21, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
25
11 Phase 3, 1 recruiting
FAERS reports
1,386
1,086 serious, 175 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 5, 2026.
XADAGO is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes. XADAGO is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes ( 1 )
Mechanism: The precise mechanism by which XADAGO exerts its therapeutic effects in PD is unknown. XADAGO is an inhibitor of monoamine oxidase B (MAO-B). Inhibition of MAO-B activity, by blocking the catabolism of dopamine, is thought to result in an increase in dopamine levels and a subsequent increase in dopaminergic activity in the brain.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- XADAGO · SAFINAMIDE MESYLATE EQ 50MG BASE · TABLET, ORAL · Prescription · TE AB
- XADAGO · SAFINAMIDE MESYLATE EQ 100MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Safinamide" as an intervention, any sponsor and status, largest first.
- Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease PatientsPivotal-lookingTerminated
Newron Pharmaceuticals SPAIndustry
NCT00865579 · 964 participants · Start Apr 2009 · Primary completion Jun 2012
Drug: Safinamide · For: Parkinson's Disease
Sites: Timuș, Romania
- MOTION, Safinamide in Early IPD, as add-on to Dopamine AgonistPivotal-lookingCompleted
Newron Pharmaceuticals SPAIndustry
NCT00605683 · 679 participants · Start Nov 2007 · Primary completion Jan 2012
Drug: Safinamide (as add-on therapy); Safinamide (as add-on therapy) and 1 more · For: Idiopathic Parkinson's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Oxnard, California · 125 sites in all
- Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's DiseasePivotal-lookingCompleted
Newron Pharmaceuticals SPAIndustry
NCT01187966 · 669 participants · Start Jan 2007 · Primary completion Oct 2008
Drug: Safinamide; Safinamide and 1 more · For: Parkinson's Disease
- Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to LevodopaPivotal-lookingCompleted
Newron Pharmaceuticals SPAIndustry
NCT00627640 · 549 participants · Start Feb 2009 · Primary completion Jan 2012
Drug: Safinimide 50-100 mg/day; Matching Placebo · For: Idiopathic Parkinson's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 121 sites in all
- 18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PDPivotal-lookingCompleted
Newron Pharmaceuticals SPAIndustry
NCT01286935 · 544 participants · Start Aug 2007 · Primary completion Apr 2010
Drug: Safinamide; Safinamide and 1 more · For: Parkinson's Disease
- MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)Pivotal-lookingTerminated
Newron Pharmaceuticals SPAIndustry
NCT01028586 · 507 participants · Start Oct 2009 · Primary completion May 2012
Drug: Safinamide, MAO-B inhibitor; Safinamide, MAO-B inhibitor and 1 more · For: Idiopathic Parkinson's Disease
Sites: Geneva, Switzerland
- A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of LevodopaPivotal-lookingCompleted
Zambon SpAIndustry
NCT03881371 · 307 participants · Start Aug 1, 2019 · Primary completion Aug 20, 2021
Drug: Safinamide · For: Parkinson Disease
Sites: Hangzhou, China; Shanghai, China; Tianjin, China · 31 sites in all
- Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine AgonistPivotal-lookingCompleted
Newron Pharmaceuticals SPAIndustry
NCT00643045 · 269 participants · Start Dec 2004 · Primary completion Jan 2006
Drug: Safinamide; Safinamide and 1 more · For: Idiopathic Parkinson's Disease
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fall177
- dyskinesia162
- hallucination159
- death108
- on and off phenomenon108
- gait disturbance104
- parkinson^s disease98
- drug ineffective95
- tremor89
- fatigue82
- freezing phenomenon78
- somnolence73
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 24 |
| 2017 | 57 |
| 2018 | 112 |
| 2019 | 152 |
| 2020 | 158 |
| 2021 | 144 |
| 2022 | 142 |
| 2023 | 117 |
| 2024 | 136 |
| 2025 | 173 |
| 2026 | 171 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xadago (Safinamide Mesylate)
2024 spending
$7.7M
Beneficiaries
759
4,385 claims
Per beneficiary
$10,116
$37.32 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $10,536,450 |
| 2021 | $10,886,772 |
| 2022 | $10,622,045 |
| 2023 | $9,872,595 |
| 2024 | $7,677,986 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- How to Optimize the Effectiveness and Safety of Parkinson's Disease Therapy? - A Systematic Review of Drugs Interactions with Food and Dietary Supplements.
Agnieszka W, Pawe P, Magorzata K · Curr Neuropharmacol 2022 · Systematic Review
- Effects of Safinamide on Motor and Non-Motor Symptoms in Patients with Parkinson's Disease and Motor Fluctuations.
Kulisevsky J, Ferraz HB, Suppa A, et al. · Eur Neurol 2024 · Meta-Analysis, Systematic Review
- Safinamide for pain management in patients with Parkinson's disease.
Abilashimova D, Aubakirova M, Abdildin Y, et al. · Rev Neurol (Paris) 2025 · Systematic Review
- The effects of safinamide according to gender in Chinese parkinsonian patients.
Pellecchia MT, Picillo M, Russillo MC, et al. · Sci Rep 2023 · Randomized Controlled Trial, Multicenter Study
- Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain.
Cattaneo C, Kulisevsky J, Tubazio V, et al. · Adv Ther 2018 · Multicenter Study, Randomized Controlled Trial
- Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Aboulatta L, Haidar L, Abou-Setta A, et al. · CNS Drugs 2023 · Meta-Analysis, Systematic Review
Sponsor: Mdd US
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.